A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hypertrophy (BPH)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hypertrophy (BPH)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Jun 2012

At a glance

  • Drugs Ozarelix (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2012 Actual patient number is 76 according to ClinicalTrials.gov.
    • 12 Jan 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top